You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

 

Online download statistics by month:

Online download statistics by month: June 2022 to July 2025

AbstractFullPdf
Jun 2022364369125
Jul 2022506520193
Aug 202216917040
Sep 202215015545
Oct 202220020048
Nov 202222622864
Dec 202213213355
Jan 202314414466
Feb 202313313570
Mar 2023707032
Apr 2023616141
May 2023596039
Jun 2023929344
Jul 202311111154
Aug 2023859037
Sep 2023777733
Oct 2023575726
Nov 2023939437
Dec 202310110155
Jan 2024646624
Feb 2024474930
Mar 2024656586
Apr 2024898945
May 2024777746
Jun 202411411563
Jul 202410910956
Aug 2024504950
Sep 20245959434
Oct 2024868647
Nov 2024899165
Dec 202410510846
Jan 2025717140
Feb 202513713841
Mar 2025686847
Apr 2025959557
May 2025565743
Jun 2025595944
Jul 2025220
Total427243212368